We are live on ! Find out more

Kailera Therapeutics

KLRA

Market cap $1.66B

12.80 USD

+0.22

1.75%

At close Updated Nov 4, 4:00 PM EST

Pre-market

After hours

12.74

-0.06

0.47%

1 day

1.75%

5 days

-5.11%

1 month

18.08%

3 months

-29.32%

6 months

-48.98%

Year to date

-50.77%

1 year

-50.77%

5 years

-50.77%

10 years

-50.77%

About: Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 87.5%

Negative 0%

Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates

Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data expected mid-2027 and mid-2028, respectively Safiglipron (KAI-7535) global Phase 2 trial fully enrolled; data now anticipated mid-2027 KAI-4729 IND now active with U.S. FDA; on track to initiate Phase 1 single-dose injection site/ethnic bridging trial by the end of 2026 Cash continues to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights.

Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates

Kailera Therapeutics to Participate in November Investor Conferences

Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences

Kailera Therapeutics to Participate in November Investor Conferences

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD).

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program.

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.

Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

Kailera Therapeutics to Participate in September Investor Conferences

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Wednesday, September 23, 2026, 9:40 a.m.

Kailera Therapeutics to Participate in September Investor Conferences

24/7 Wall Street

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore

Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap.

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the second quarter ended June 30, 2026, and provided a summary of recent business highlights.

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over $1.3 billion post-IPO—funds operations through mid-2028, supporting multiple pivotal trial readouts before further capital is needed. Pipeline catalysts include global Phase 3 trials for ribupatide and promising Phase 2/3 data for oral GLP-1 candidates, targeting differentiated efficacy and convenience.

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

Why Is Kailera Therapeutics Stock Falling Tuesday?

Kailera Therapeutics Inc. (NASDAQ:KLRA) stock fell about 9% on Tuesday after the company reported positive topline results from two Phase 3 trials of its oral GLP-1 drug candidate HRS-7535/KAI-7535 in China.

Why Is Kailera Therapeutics Stock Falling Tuesday?

See News Rankings

Price charts implemented using Lightweight Charts™